IQVIA (IQV) to Report Q4 Earnings: What's in the Offing?
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
Stay Ahead of the Game With IQVIA (IQV) Q4 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics...
IQVIA (IQV) Climbs 17% in 3 Months: Here's What to Know
IQVIA (IQV) benefits from revenue growth and disciplined cost management.
IQVIA (IQV) Stock Gains 8% in a Month: Here's What to Know
IQVIA (IQV) aims at market expansion through innovation and service improvements.
Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQVIA: I Would Stay Away Until Debt Issues Are Resolved
IQVIA is a global provider of contract research services and data analytics for the healthcare industry. The company helps clients drive healthcare forward by providing insights and solutions to im...
IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.48 per share a year ago.
IQVIA (IQV) to Report Q3 Earnings: What's in the Offing?
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
IQVIA (IQV) and argenx Partner to Advance Autoimmune Care
IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative pharmacovigilance.
Court strikes down federal rule that sharply increased prescription costs for many patients
A federal court on Friday struck down a rule that sharply increased out-of-pocket prescription costs for many patients with complex conditions.
Here's Why Investors Should Retain IQVIA (IQV) Stock Now
An addressable market size and strong healthcare-specific global IT infrastructure boost IQVIA (IQV).
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried abo...
IQVIA (IQV) Stock Improves 8% in Three Months: Here's How
IQVIA (IQV) aims at market expansion through innovation and service improvements.
Related Companies